CCIA
CRSP icon

Campbell & Co Investment Adviser’s CRISPR Therapeutics CRSP Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,322
Closed -$861K – 1103
2024
Q3 		$861K Buy
+18,322
New +$930K 0.06% 497
2024
Q2 		– Sell
-8,918
Closed -$608K – 1087
2024
Q1 		$608K Sell
8,918
-9,856
-52% -$706K 0.05% 616
2023
Q4 		$1.18M Buy
+18,774
New +$1.04M 0.11% 317

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Campbell & Co Investment Adviser's CRSP Position: Q4 2024 in Review

Campbell & Co Investment Adviser sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 18,322 shares — an estimated $861K sold.

Campbell & Co Investment Adviser first reported a position in CRSP in Q4 2023 and held it in 3 quarters. The position peaked at $1.18M in Q4 2023. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Campbell & Co Investment Adviser reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 18,322 CRISPR Therapeutics shares in Q4 2024, an estimated $861K.
  • Campbell & Co Investment Adviser first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's CRISPR Therapeutics position peaked at $1.18M in Q4 2023.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2024, filed 10 Feb 2025.